Forgot password

The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

UPCOMING EDUCATIONAL OPPORTUNITIES

Lunchtime webinar Series

January 30, 2025 at 12:15pm

Recognizing Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) in Patient Care

OCN Review Course

NNECOS OCN Review Courses

March 21, 2025

September 15, 2025

SPRING MEETING

*NEW* NNECOS Spring Meeting
May 3, 2025


ANNUAL MEETING

NNECOS Annual Meeting
October 24-25, 2025

RESEARCH, PROJECT & PROGRAM FUNDING


Spring Submission Deadline - March 15th


Spring Submission Deadline

March 15th


Up to $4,000 to fund your educational program.

Rolling Application Deadline

NNECOS PATIENT PHILANTHROPY


Rolling Application Deadline

Up to $3,000 per grant


Rolling Application Deadline

Up to 125, $25 grocery/cards 


OTHER NEWS & INFORMATION

New! Patient Advisor!

NNECOS is delighted to announce the appointment of Tawnya McDonald as the inaugural NNECOS Patient/Caregiver Advisor. Tawnya will serve as a partner to the NNECOS Board of Directors, sharing feedback, generating ideas, and offering insight from a patient perspective, providing invaluable opinoins based on personal experience with aspects of care. 

NNECOS Classifieds

Visit the NNECOS Member Classifieds for more information about job listings from the following centers:

  • UVM Cancer Center, Larner College of Medicine 

  • Dartmouth Cancer Center

  • UVM Cancer Center

  • Beth Israel Lahey Health Exeter

Drug Shortages Sign On Letter

https://asco.quorum.us/campaign/56411/

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



SOCIAL MEDIA

 

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Participate on a NNECOS Task Force


FDA Approvals & uPDATES

Latest FDA Approval

  • December 27 - FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
  • December 20 - FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation
  • December 18 - FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer
  • December 18 - FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients

  • December 13 - FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma

  • December 4 - FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma
  • November 20 - FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer
  • November 19 - FDA approves updated drug labeling for fludarabine phosphate under Project Renewal
  • November 15 - FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
  • November 8 - FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
  • October 29 - FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
  • October 18 - FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
  • October 10 - FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
  • October 3 - FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer


Package/Label Updates


    Code Updates

    • Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    Thank You Corporate Members!


    THANK YOU DIAMOND & PLATINUM CORPORATE MEMBERS























    View the complete list of corporate members.

    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software